# Efficacy of selinexor combined with subcutaneous decitabine in myeloid malignancies refractory to or relapsed after venetoclax therapy

## TL;DR

This study explores the effectiveness and safety of combining selinexor and subcutaneous decitabine in treating myeloid malignancies that have failed venetoclax therapy.

## Contribution

The study introduces a novel treatment combination for patients refractory or relapsed after venetoclax therapy.

## Key findings

- The treatment showed partial responses in some AML and MDS patients.
- Most patients experienced manageable side effects like bone marrow suppression and mild gastrointestinal reactions.
- The median duration of response was 2 months for the six effective cases.

## Abstract

维奈克拉（Ven）目前在临床应用的范围越来越广，不管是急性髓系白血病（AML）还是高危骨髓增生异常综合征（MDS），既往Ven治疗后失败的患者，再诱导方案的选择尚无统一标准。本文对10例既往Ven治疗失败的AML和伴原始细胞增多1/2型MDS患者，采用塞利尼索（Selinxor）联合皮下注射地西他滨进行治疗，对其疗效和安全性进行回顾性总结，并结合文献复习。7例AML患者中，完全缓解（CR）1例，CR伴不完全血液学恢复2例，部分缓解1例，未缓解2例，疾病进展1例；3例MDS患者中，骨髓完全缓解2例，疾病稳定1例。6例有效患者的中位缓解持续时间为2（0.5～6）个月。10例患者均出现不同程度的骨髓抑制，5例患者出现轻微胃肠道反应，但均在可控的范围内，整体耐受性良好，没有患者因治疗不良反应而死亡。表明塞利尼索联合皮下注射地西他滨为Ven治疗失败的患者提供了一种新的治疗手段，且耐受性良好。